Prelude Therapeutics, Inc. (PRLD)

Over the past six months, Prelude Therapeutics' stock (PRLD) has experienced significant movements, including a substantial increase of 142.54% from January 8, 2025, to January 8, 2026, and a 61.35% increase in the month leading up to January 14, 2026. On November 3, 2025, the stock price jumped by 150.31% due to speculation of a potential buyout deal and investor optimism. Prelude Therapeutics announced a strategic business update on November 4, 2025. On November 12, 2025, the company reported its third-quarter 2025 financial results, with an EPS of -$0.26, surpassing analyst expectations, and revenue reaching $6.5 million. On December 6, 2025, Prelude Therapeutics presented data from its Myeloproliferative Neoplasm (MPN) Programs at the 2025 ASH Annual Meeting. On December 8, 2025, Citizens reiterated a "Market Outperform" rating and a $3.00 price target for PRLD. On December 29, 2025, shares closed up 20.00%, driven by positive coverage highlighting the Q3 2025 earnings beat and an extended cash runway through 2027. On January 6, 2026, shares closed up 10.55%, attributed to positive social media attention regarding the company's oncology pipeline progress. Insider sentiment has been positive, with 13 different insiders making open-market purchases in October and November 2025.

Traditional demand seasonality is not applicable to Prelude Therapeutics' business model as a clinical-stage precision oncology company. The company's revenue and financial performance are more likely influenced by factors such as the progress of its clinical trials, regulatory milestones, collaborations, and funding rounds.

Prelude Therapeutics, Inc. (PRLD) is a clinical-stage precision oncology company focused on discovering and developing innovative drug candidates targeting critical cancer cell pathways, operating within the Healthcare sector, specifically the Biotechnology or Pharmaceuticals & Biotech industry. The company's pipeline includes drug candidates such as PRT1419, PRT2527, PRT3645, PRT3789, PRT7732, KAT6A degraders, JAK2V617F JH2 inhibitors, and Degrader Antibody Conjugates (DACs).

Prelude Therapeutics, Inc. is headquartered in Wilmington, Delaware, United States and primarily serves throughout the US.

Prelude Therapeutics' brand reputation has been influenced by its scientific advancements and financial updates. Positive sentiment has been garnered due to breakthroughs in clinical trials and progress in its oncology pipeline, as well as positive analyst ratings and price targets. However, reports of investigations by the Pomerantz Law Firm on behalf of investors could indicate events that negatively impacted the company's reputation.

The ownership structure of Prelude Therapeutics (PRLD) includes institutional, insider, and retail investors. Institutional investors hold approximately 33.70% to 43.21% of the company's stock. Insiders own approximately 39.52% to 52.21% of the stock. Retail investors hold around 4.58% to 22.21% of the shares.